Anzeige
Mehr »
Login
Samstag, 28.09.2024 Börsentäglich über 12.000 News von 691 internationalen Medien
Von 0,059 € auf 0,26 €: Die Gold-Aktie, die alle Erwartungen übertrifft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
298 Leser
Artikel bewerten:
(1)

Emergent Health Corp.: Emergent Executes Letter of Intent to Partner with Lumina to Commence its "Content Based Marketing" Initiative Through Influencers

NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Emergent Health Corp. (OTC PINK:EMGE) announces it has executed a letter of intent to partner with Lumina Industries, Inc. ("Lumina"), the world's first Artificial Intelligence ("AI") webcam to commence its "Content Based Marketing" Initiative through Influencers.

Emergent Health Corp., Tuesday, November 22, 2022, Press release picture

Lumina is a tiny, premium webcam that provides adaptive color correction, a realistic depth of field effect, and AI features - including adjustable bokeh and cameraman effects - so you'll always look your best. The Lumina software detects your face and smooths it, detects the background and adds some blur.

Emergent has commenced its marketing initiative by enlisting Influencers to spread the word of the products developed and being developing through its subsidiaries Evolutionary Biologics and PharmaZu

Subject to the completion of the Partnership Agreement, Emergent will be purchasing Lumina 4K webcams and providing the webcams free of charge to its Influencers to enhance the Emergent consumer experience of "Content Based Shopping" of its products.

Shoppable content is any type of content (i.e. videos, articles, images, etc) that provides a direct purchasing opportunity and allows consumers to add products to a cart from what they are viewing - or at the very least, get referred to a product page and continue to shop from there. This means that there's just one click - or two, at a maximum - between the Aha! moment, when people see the product they desire, to the Finally! moment, when they can actually buy it. By making content shoppable, brands allow their customers to flip through articles, videos, snaps and photos, and, with the mere tap of a finger, instantly purchase the items they desire. Convenience isn't the only factor propelling shoppable content to the top of CMOs' minds; it's ability to provide relevant items to consumers based on their interests is a huge opportunity as well, since 78% of consumers report desiring some degree of personalized content. Shoppable content simplifies the path to purchase as it leads directly from content to cart - something that traditional content isn't capable of doing.

Marvin Segel, CMO of Emergent and son of QVC Founder Joseph Segel stated, "Great Content Is Key", but that content must be in focus and have great audio too. Marvin Segel personally uses LUMINA and it is simple to set up and operate and has built in Artificial Intelligence to follow you and keep you in frame as you move. It clips to the top of your computer or monitor or can be used on a small tripod".

ABOUT EMERGENT HEALTH CORPORATION

Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter.

Before using any products, you should always consult with your Veterinarian and/or Family Doctor.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR MORE INFORMATION, PLEASE CONTACT:

Jim Morrison, CEO
Emergent Health Corporation Website
info@emergenthealthcompany.com

SOURCE: Emergent Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/727929/Emergent-Executes-Letter-of-Intent-to-Partner-with-Lumina-to-Commence-its-Content-Based-Marketing-Initiative-Through-Influencers

© 2022 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.